COMMUNIQUÉS West-GlobeNewswire
-
Clinical Match Me Announces Strategic Partnership with NPACE
30/09/2025 -
Sequana Medical’s alfapump® System Featured in Presentation at 2025 Portal Intervention Symposium
30/09/2025 -
Major Wellbeing Organization Selects Aino’s SaaS Platform
30/09/2025 -
BEYOND IMMORTALITY: European Wellness Biomedical Group Charts Longevity Through Cell Regeneration Over Organ Transplant
30/09/2025 -
Change in Board’s Composition
30/09/2025 -
Evolution de la composition du Conseil d’administration
30/09/2025 -
AiM Medical Robotics Secures $8.1 Million Series A Financing to Transform Neurosurgery with MRI-Compatible Surgical Robotics
30/09/2025 -
PETVIVO HOLDINGS, INC. ANNOUNCES CLOSE OF NOTE CONVERSION AGREEMENTS TO EXTINGUISH OVER TWO MILLION DOLLARS OF OUTSTANDING DEBT
30/09/2025 -
Total number of shares and voting rights in Zealand Pharma as of September 30, 2025
30/09/2025 -
Cannabix Technologies Announces First Sale of BreathLogix Alcohol Screening Device to Maritime Market
30/09/2025 -
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
30/09/2025 -
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
30/09/2025 -
FDA Clears OsteoProbe® (K250216): First-Ever Device Indication for Measuring Bone Material Strength
30/09/2025 -
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
30/09/2025 -
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30/09/2025 -
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
30/09/2025 -
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
30/09/2025 -
Medera Strengthens Leadership Team with Three Key Executive Appointments
30/09/2025 -
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
30/09/2025
Pages